Conditions: Chronic Myeloid Leukemia in Chronic Phase
Keywords: Refractory Chronic Myeloid Leukemia in Chronic Phase adults oral LBH589
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 29
Healthy volunteers: no

Brief summary:
This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors

Detailed description:

Arms:
arm 1: Participants were administered panobinostat 20 milligram (mg) orally once a day (OD) three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat were administered at the same time each morning with 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue treatment until they experienced unacceptable toxicity or disease progression.

Interventions: intervention 1: LBH589
Intervention descriptions: intervention 1: None

Protocol document: